GBI invited Jeffrey Zhang, strategy vice president at WuXi Apptec and rotating chairman of China Healthcare Business Development (CHBD), for the benefit of his years of pharma business development experience. He talked us through the impact of the "4+7” volume-based procurement program, recent pharmaceutical industry merger and acquisition trends, innovative drug research and development and others.